IRulya Therapeutics Inc. cotiza a 32.03 USD y tiene una capitalización bursátil de $33M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T,…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-04 |
|---|---|---|---|---|
| Real | — | $-12.15 | $57.60 | $-152.00 |
| Estimado | $-1.20 | $-12.39 | $-52.00 | $-45.00 |
| Sorpresa | — | +1.9% | +210.8% | -237.8% |
| Métrica | IRLA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 56.7% | — |
| Operating Margin | — | -39.1% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -14.0% | — |
| ROE | — | -40.4% | — |
| ROA | -89.8% | -32.0% | -57.8% |
| Current Ratio | 0.53 | 2.85 | -2.32 |
| Debt / Equity | 0.00 | 0.27 | -0.27 |